Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Br J Haematol. 2023 Dec;203(5):774-780. doi: 10.1111/bjh.19037. Epub 2023 Aug 16.

Abstract

Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.

Keywords: CNS; cellular therapies; non-Hodgkin lymphoma.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antigens, CD19
  • Cell- and Tissue-Based Therapy
  • Central Nervous System
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Immunotherapy, Adoptive / methods
  • Lymphoma, Mantle-Cell* / drug therapy
  • Neurotoxicity Syndromes* / drug therapy
  • Receptors, Antigen, T-Cell / therapeutic use
  • Receptors, Chimeric Antigen* / therapeutic use
  • T-Lymphocytes
  • Treatment Outcome

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell
  • Antigens, CD19